Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | ZELLA 101: alvocidib for newly diagnosed AML

Joshua Zeidner • 8 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Alvocidib Cytarabine Daunorubicin Mitoxantrone
ZELLA 101

Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses results from the Phase I ZELLA 101 study of alvocidib, a CDK9 kinase inhibitor, for newly diagnosed acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Joshua Zeidner

Menin inhibitors in AML: combinations, resistance, and future directions 12:28
Menin inhibitors in AML: combinations, resistance, and future directions
Amir Fathi et al. • 19 Sep 2025
BEAT AML trial update: revumenib + aza-ven in older adults with NPM1-mutated or KMT2A-rearranged AML 2:12
BEAT AML trial update: revumenib + aza-ven in older adults with NPM1-mutated or KMT2A-rearranged AML
Joshua Zeidner • 14 Jun 2025
Phase I results of the menin inhibitor enzomenib in patients with R/R acute leukemia 2:11
Phase I results of the menin inhibitor enzomenib in patients with R/R acute leukemia
Joshua Zeidner • 9 Dec 2024
SLS009, a CDK9 inhibitor, with azacitidine and venetoclax for R/R AML after prior venetoclax therapy 2:07
SLS009, a CDK9 inhibitor, with azacitidine and venetoclax for R/R AML after prior venetoclax therapy
Joshua Zeidner • 9 Dec 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals